WO2008019303A3 - Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors - Google Patents

Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors Download PDF

Info

Publication number
WO2008019303A3
WO2008019303A3 PCT/US2007/075146 US2007075146W WO2008019303A3 WO 2008019303 A3 WO2008019303 A3 WO 2008019303A3 US 2007075146 W US2007075146 W US 2007075146W WO 2008019303 A3 WO2008019303 A3 WO 2008019303A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
serine protease
hepatitis
pyridazinonyl
compounds
Prior art date
Application number
PCT/US2007/075146
Other languages
French (fr)
Other versions
WO2008019303A2 (en
Inventor
Joel D Moore
Datong Tang
Yat Sun Or
Zhe Wang
Original Assignee
Enanta Pharm Inc
Joel D Moore
Datong Tang
Yat Sun Or
Zhe Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/832,893 external-priority patent/US7718612B2/en
Application filed by Enanta Pharm Inc, Joel D Moore, Datong Tang, Yat Sun Or, Zhe Wang filed Critical Enanta Pharm Inc
Publication of WO2008019303A2 publication Critical patent/WO2008019303A2/en
Publication of WO2008019303A3 publication Critical patent/WO2008019303A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
PCT/US2007/075146 2006-08-04 2007-08-03 Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors WO2008019303A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49984406A 2006-08-04 2006-08-04
US11/499,844 2006-08-04
US11/832,893 US7718612B2 (en) 2007-08-02 2007-08-02 Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
US11/832,893 2007-08-02

Publications (2)

Publication Number Publication Date
WO2008019303A2 WO2008019303A2 (en) 2008-02-14
WO2008019303A3 true WO2008019303A3 (en) 2008-10-30

Family

ID=39033583

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/075146 WO2008019303A2 (en) 2006-08-04 2007-08-03 Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors

Country Status (4)

Country Link
CO (1) CO6020004A1 (en)
EC (1) ECSP077649A (en)
PE (1) PE20080539A1 (en)
WO (1) WO2008019303A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227940B2 (en) 2002-05-20 2016-01-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI387603B (en) 2005-07-20 2013-03-01 Merck Sharp & Dohme Hcv ns3 protease inhibitors
KR20080056295A (en) 2005-10-11 2008-06-20 인터뮨, 인크. Compounds and methods for inhibiting hepatitis c viral replication
RU2008152171A (en) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) NEW HEPATITIS C VIRAL REPLICATION INHIBITORS
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (en) 2008-09-11 2010-04-30 Enanta Pharm Inc HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS
EP2417134B1 (en) 2009-04-08 2017-05-17 Idenix Pharmaceuticals LLC. Macrocyclic serine protease inhibitors
EP2432318A4 (en) * 2009-05-22 2012-11-21 Sequoia Pharmaceuticals Inc Bimacrocyclic hcv ns3 protease inhibitors
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
SG188957A1 (en) 2010-01-25 2013-05-31 Enanta Pharm Inc Hepatitis c virus inhibitors
WO2012092411A2 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc. Phenanthridine macrocyclic hepatitis c serine protease inhibitors
CN103534256B (en) 2010-12-30 2016-08-10 益安药业 Macrocyclic hepatitis c serine protease inhibitors
AR085352A1 (en) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc MACROCICLIC INHIBITORS OF SERINA PROTEASA, ITS PHARMACEUTICAL COMPOSITIONS AND ITS USE TO TREAT HCV INFECTIONS
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6154474B2 (en) 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Hepatitis C virus inhibitor
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072243A2 (en) * 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis c serine protease inhibitors
US20040180815A1 (en) * 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
US20050153877A1 (en) * 2003-02-07 2005-07-14 Zhenwei Miao Macrocyclic hepatitis C serine protease inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072243A2 (en) * 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis c serine protease inhibitors
US20050153877A1 (en) * 2003-02-07 2005-07-14 Zhenwei Miao Macrocyclic hepatitis C serine protease inhibitors
US20040180815A1 (en) * 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227940B2 (en) 2002-05-20 2016-01-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Also Published As

Publication number Publication date
WO2008019303A2 (en) 2008-02-14
ECSP077649A (en) 2008-03-26
PE20080539A1 (en) 2008-05-16
CO6020004A1 (en) 2009-03-31

Similar Documents

Publication Publication Date Title
WO2008019303A3 (en) Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors
WO2007143694A3 (en) Macrocyclic oximyl hepatitis c protease inhibitors
WO2008021960A3 (en) Triazolyl macrocyclic hepatitis c serine protease inhibitors
WO2008022006A3 (en) Arylalkoxyl hepatitis c virus protease inhibitors
WO2008019289A3 (en) Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
WO2008021956A3 (en) Acylaminoheteroaryl hepatitis c virus protease inhibitors
WO2008019266A3 (en) Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
WO2008021871A3 (en) Triazolyl acyclic hepatitis c serine protease inhibitors
WO2008002924A3 (en) Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
WO2009076166A3 (en) Oximyl hcv serine protease inhibitors
WO2008021733A3 (en) Tetrazolyl acyclic hepatitis c serine protease inhibitors
MX2010005261A (en) Macrocyclic tetrazolyl hepatitis c serine protease inhibitors.
WO2009053828A3 (en) P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors
MX2010006518A (en) Macrocyclic oximyl hepatitis c serine protease inhibitors.
MX2010006209A (en) Quinoxalinyl derivatives.
MX2010005262A (en) Quinoxaline-containing compounds as hepatitis c virus inhibitors.
MX2010010276A (en) Fluorinated macrocyclic compounds as hepatitis c virus inhibitors.
WO2009076173A3 (en) Fluorinated tripeptide hcv serine protease inhibitors
WO2004093798A3 (en) Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors
WO2004113365A3 (en) Hepatitis c serine protease tri-peptide inhibitors
MX2011012155A (en) Macrocyclic compounds as hepatitis c virus inhibitors.
WO2011049908A3 (en) Bismacrokyclic compounds as hepatitis c virus inhibitors
MX2019013037A (en) Macrocyclic proline derived hcv serine protease inhibitors.
WO2009085978A8 (en) Bridged carbocyclic oxime hepatitis c virus serine protease inhibitors
MX2010008109A (en) Difluorinated tripeptides as hcv serine protease inhibitors.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07799997

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07799997

Country of ref document: EP

Kind code of ref document: A2